Figure 4.
Incorporation of etoposide into the therapeutic regimens is associated with improved survival in patients with OHI+ lymphoma. Kaplan-Meier curves of OHI+ patients (sCD25 >3900 U/mL and ferritin >1000 ng/mL) in the cohort stratified by use of HLH-directed treatments (A). (B) Bar plots of the percentage of lymphoma responses as defined by the Lugano criteria after the first line of therapy. Statistical analyses were conducted using the Fisher exact test; Kaplan-Meier curves of patients with lymphoma in the cohort stratified by inclusion of etoposide in the malignancy-directed therapeutic regimen, in OHI+ (C) and OHI− (D) B-NHL, and OHI+ (E) and OHI− (F) T-cell lymphoma. The number at risk is presented for each group. Statistical analysis was performed using the log-rank (Mantel-Cox) test, and the P values are presented on the plots. CR, complete response; PR, partial response; SD, stable disease; TCL, T-cell lymphoma.

Incorporation of etoposide into the therapeutic regimens is associated with improved survival in patients with OHI+ lymphoma. Kaplan-Meier curves of OHI+ patients (sCD25 >3900 U/mL and ferritin >1000 ng/mL) in the cohort stratified by use of HLH-directed treatments (A). (B) Bar plots of the percentage of lymphoma responses as defined by the Lugano criteria after the first line of therapy. Statistical analyses were conducted using the Fisher exact test; Kaplan-Meier curves of patients with lymphoma in the cohort stratified by inclusion of etoposide in the malignancy-directed therapeutic regimen, in OHI+ (C) and OHI− (D) B-NHL, and OHI+ (E) and OHI− (F) T-cell lymphoma. The number at risk is presented for each group. Statistical analysis was performed using the log-rank (Mantel-Cox) test, and the P values are presented on the plots. CR, complete response; PR, partial response; SD, stable disease; TCL, T-cell lymphoma.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal